Accumulation of 111In-neutrophils in rabbit skin in allergic and non-allergic inflammatory reactions in vivo. Inhibition by neutrophil pretreatment in vitro with a monoclonal antibody recognizing the CD18 antigen.
The mAb 60.3 recognizes the neutrophil CD18 Ag. We have investigated the effect of in vitro pretreatment of radiolabeled neutrophils with mAb 60.3 on their accumulation in vivo. Further, we have compared the in vivo effects of mAb 60.3 with its effects on neutrophil adherence in vitro. Neutrophil accumulation in vivo was measured in response to: 1) exogenous mediators FMLP, C5a des Arg, LTB4 and IL-1; 2) endogenous mediators generated in a non-allergic inflammatory reaction induced by zymosan; and 3) endogenous mediators generated in two allergic inflammatory reactions, a passive cutaneous anaphylactic reaction and a reversed passive Arthus reaction in rabbit skin. Pretreatment of neutrophils with mAb 60.3 inhibited their accumulation in all the responses. The results demonstrate that there is a common mechanism mediating neutrophil accumulation in these inflammatory reactions. Neutrophils pretreated with mAb 60.3 were also unresponsive to chemoattractants in in vitro adherence assays. However, the antibody-treated neutrophils responded normally to FMLP and C5a with respect to granular enzyme release. These results suggest that the basal expression of CD18 Ag is important for the adherence of neutrophils to microvascular endothelial cells stimulated by the local generation, or administration, of chemical mediators in vivo. Despite the fact that mediators such as FMLP can increase CD18 expression in vitro, it appears more likely that such mediators act in vivo by inducing a conformational change in the basally expressed neutrophil adhesive molecules.
Nourshargh
S
S
MRC Clinical Research Centre, Section of Vascular Biology, Harrow, Middlesex, England.
Rampart
M
M
Hellewell
P G
PG
Jose
P J
PJ
Harlan
J M
JM
Edwards
A J
AJ
Williams
T J
TJ
D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D001183:Arthus Reaction / Q000276:immunology; D018821:CD18 Antigens; D002448:Cell Adhesion; D003594:Cytoplasmic Granules / Q000201:enzymology; D005434:Flow Cytometry; D005455:Fluorescent Antibody Technique; D006967:Hypersensitivity / Q000276:immunology / Q000473:pathology*; D007166:Immunosuppressive Agents / Q000494:pharmacology; D007205:Indium Radioisotopes / Q000378:metabolism; D007249:Inflammation / Q000473:pathology; D007271:Injections, Intradermal; D008297:Male; D008562:Membrane Glycoproteins / Q000276:immunology*; D009504:Neutrophils / Q000201:enzymology / Q000276:immunology / Q000473:pathology*; D010323:Passive Cutaneous Anaphylaxis; D011817:Rabbits; D012867:Skin / Q000473:pathology*; D015054:Zymosan / Q000008:administration & dosage
D000911:Antibodies, Monoclonal; D018821:CD18 Antigens; D007166:Immunosuppressive Agents; D007205:Indium Radioisotopes; D008562:Membrane Glycoproteins; D015054:Zymosan